PreveMama is an application developed by GooApps® in collaboration with the Ramón y Cajal University Hospital and the Ramón y Cajal Institute for Health Research (IRYCIS). Its goal is to facilitate the individual assessment of breast cancer risk in adult women through the use of a clinically validated predictive model.
The app is based on the RC-1 Score, a prediction tool developed and validated by the IRYCIS team, led by Dr. Miguel Martín Hernández (Medical Oncology) and Dr. Javier Martín Sánchez (Preventive Medicine), both members of the research group Prevention, Diagnosis and Treatment of Breast Cancer.
PreveMama calculates the 5-year risk by taking into account age, family history, personal medical history, and lifestyle factors. It also includes updated scientific references, screening recommendations, and educational materials to support informed decision-making.
A Venture-as-a-Service case in public health
PreveMama exemplifies how Goo Ventures partners with clinical institutions to turn scientific knowledge into useful and accessible digital solutions. Within the Venture-as-a-Service model, GooApps® was responsible for UX/UI design, technological development, legal compliance, and secure deployment of the tool, enabling IRYCIS to focus its expertise on clinical content and scientific validation.
Project sponsors
The development of PreveMama has been supported by three global leaders in the pharmaceutical sector:
- Lilly
- Novartis
- Pfizer
Their support demonstrates these companies’ commitment to prevention, women’s health, and evidence-based medical innovation.
